NCT04515394 2022-12-22
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
EMD Serono
Phase 2 Terminated
EMD Serono
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany